Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-28T14:42:53.644Z Has data issue: false hasContentIssue false

Role of n−6 PUFA derived lipid mediators on epithelial barrier function in intestinal Caco-2 cell monolayers

Published online by Cambridge University Press:  04 June 2010

M. J. Rodríguez-Lagunas
Affiliation:
Departamento de Fisiologia, Facultat de Farmàcia, Universitat de Barcelona, Av. Joan XXIII s/n, Barcelona and Institut dInvestigació en Nutrició i Seguretat Alimentaria
R. Martín-Venegas
Affiliation:
Departamento de Fisiologia, Facultat de Farmàcia, Universitat de Barcelona, Av. Joan XXIII s/n, Barcelona and Institut dInvestigació en Nutrició i Seguretat Alimentaria
J. J. Moreno
Affiliation:
Departamento de Fisiologia, Facultat de Farmàcia, Universitat de Barcelona, Av. Joan XXIII s/n, Barcelona and Institut dInvestigació en Nutrició i Seguretat Alimentaria
R. Ferrer
Affiliation:
Departamento de Fisiologia, Facultat de Farmàcia, Universitat de Barcelona, Av. Joan XXIII s/n, Barcelona and Institut dInvestigació en Nutrició i Seguretat Alimentaria
Rights & Permissions [Opens in a new window]

Abstract

Type
Abstract
Copyright
Copyright © The Authors 2009

The intestinal epithelium forms a regulated and selectively permeable barrier that allows transcellular and paracellular passage of luminal nutrients, water and ions, but restricts the access of potentially harmful substances. Several intestinal diseases are associated with the disruption of epithelial barrier function, particularly inflammatory bowel disease (IBD)(Reference Turner1). Although it is not clear whether intestinal barrier dysfunction is involved in the initiation or is the result of intestinal inflammation, it is likely that this dysfunction may perpetuate the stimulation of the mucosal immunity. In fact, epithelial cells are recognized to play a key role in the innate and adaptive immune responses.

Eicosanoids are lipid mediators synthesized from membrane arachidonic acid (n-6 PUFA) through three distinct pathways: cyclooxygenase (COX), lipooxygenase (LOX) and cytochrome P450 pathways. We recently demonstrated that the addition of prostaglandin E2 (PGE2) to differentiated Caco-2 cells induces the disruption of epithelial barrier function(Reference Martin-Venegas, Roig-Perez and Ferrer2). Moreover, this eicosanoid is increased in the mucosa of IBD patients(Reference Hommes, Meenan and de Haas3, Reference Berg, Zhang and Weinstock4). The objective of this study was to investigate in differentiated Caco-2 cell monolayers, the potential of different eicosanoids to disrupt paracellular permeability (PP). For this purpose, the cells were grown on polycarbonate filters with a pore size of 0.4 μm (Transwell®, 4×105 cells/cm2) for 21 days. PP was assessed from transepithelial electrical resistance (TER) and apical to basolateral D-mannitol fluxes (0.4 μCi/ml D-[2-3H]mannitol) in cultures maintained for 3 h with different eicosanoids in the apical and basolateral compartments.

In contrast to PGE2, PGD2, another COX pathway derived product, did not modify PP. As for the LOX pathway, 5-, 12- and 15-hydroxyeicosatetraenoic acids (5-, 12(R)-, 12(S)- and 15-HETE) increased PP although 12(R)- and 12(S)-isomers did not change TER. Another LOX metabolite, leukotriene B4 (LTB4) did not exert any effect, whereas LTD4 increased D-mannitol fluxes without changes on TER. Finally, the cytochrome P450 products, 11,12- and 14,15- epoxyeicosatrienoic acids (11,12- and 14,15-EET) did not alter epithelial barrier function.

Table 1. Effect of eicosanoids on PP expressed as percentage of the treatment condition with respect to the control condition (means±sem)

*P<0.05 v. control (11.67±0.79 fmol/cm2, 200.39±2.63 Ω.cm2).

In conclusion, we have demonstrated that different eicosanoids are able to disrupt epithelial barrier function leading to the diffusion of luminal solutes as well as pathogens and toxins through the intercellular space thus triggering mucosal immune responses.

This study was supported by grant BFU2007-61727/BFI (Ministerio de Ciencia y Tecnología) and 2005SGR0269 (Generalitat de Catalunya).

References

1.Turner, JR (2006) Am J Pathol 169, 19011909.CrossRefGoogle Scholar
2.Martin-Venegas, R, Roig-Perez, S, Ferrer, R et al. (2006) J Lipid Res 47, 14161423.CrossRefGoogle Scholar
3.Hommes, DW, Meenan, J, de Haas, M et al. (1996) Gut 38, 564567.CrossRefGoogle ScholarPubMed
4.Berg, DJ, Zhang, J, Weinstock, JV et al. (2002) Gastroenterology 123, 15271542.CrossRefGoogle Scholar
Figure 0

Table 1. Effect of eicosanoids on PP expressed as percentage of the treatment condition with respect to the control condition (means±sem)